A coating composition includes, in relation to 100% of the weight thereof: between 10 and 90 wt. % of at least one film-forming polymer selected from cellulosic polymers or derivatives of cellulosic polymers, derivatives of vinyl alcohol, derivatives of vinyl pyrrolidones, polymers of a natural origin, acrylic or methacrylic derivatives, derivatives of glycol or propylene glycol or combinations of the two substances or the copolymers of vinyl alcohol and polyethylene glycol (PEG); between 1 and 50 wt. % of at least one food colouring agent; and between 0 and 50 wt. % of at least one auxiliary coating agent selected from white opacifiers, diluents, surfactants, plasticizers, and anti-foaming agents.

Disclosed is a capsule, tablet or pill comprising a formulation at least two of the fat-soluble vitamins vitamin A, vitamin D, vitamin E and vitamin K; and one or more kinds of medium-chain triglyceride; also disclosed are foods, drinks and pharmaceutical compositions comprising the capsule, tablet or pill; and methods of treatment of a patient comprising administration of an effective amount of the capsule, tablet or pill. The capsule, tablet or pill is particularly, but not exclusively, suitable for use in treating cystic fibrosis patients.

Oral tablet comprising as active principle an association of dry extracts of turmeric, pomegranate and Boswellia, with colonic release, wherein said release is guaranteed by the presence of a combination of sodium alginate and hydroxypropyl methylcellulose in the relative matrix in which the aforementioned active ingredients are dispersed. This oral tablet, preferably in the form of a food supplement, is employed as co-adjuvant in the treatment and prevention of colonic disorders caused by suspected or confirmed alteration of the inflammatory situation and destabilization of the microbiota.

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including Type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the present invention relates to compositions and methods which may be used to treat, inhibit or reduce the likelihood of hepatitis viral infections, including Hepatitis B and Hepatitis C viral infections, as well as the secondary disease states and/or conditions which are often associated with such viral infections, including hepatic steatosis (steatohepatitis), cirrhosis, fatty liver and hepatocellular cancer, among other disease states or conditions.

A method for making a controlled release material, comprising the steps of: — (a) forming granules comprising one or more wax and one or more disintegrant; (b) spheronisation of the granules and (c) compaction of the spheronised granules of step so as to form the controlled release material. The invention also relates to a tablet and delayed and sustained release material made according to the method.

The present invention provides novel pharmaceutical compositions of dimethyl fumarate. The pharmaceutical compositions of the present invention are in the form of a bead and comprise (i) an inert core; (ii) a first layer surrounding the inert core, wherein the first layer comprises dimethyl fumarate; and (iii) an enteric coating surrounding the first layer. Also provided are pharmaceutical compositions in the form of a bead comprising a core and an enteric coating surrounding the core, wherein the core comprises dimethyl fumarate. Methods of using the pharmaceutical compositions of the present invention for treating multiple sclerosis are also included.

The present invention relates to tablet dosage formulations of oleyl phosphocholine for oral administration and the processes for their preparation. Specifically, the present invention provides a process for preparing an oleyl phosphocholine containing granulate, said process comprising a blending step, a hot melt agglomeration step and a milling step. The present invention further provides a process for preparing a tablet comprising the oleyl phosphocholine containing granulate, said process comprising the step of preparing an OIPC containing granulate according to the invention, a blending step, a compression step, and optionally a coating step. The invention further provides any intermediate and/or en product resulting from these steps and processes.

The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNFα), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions that preserve the coating of coated API particles in a pharmaceutical suspension. Pharmaceutical compositions include coated active pharmaceutical ingredient (API) particles comprising: an API particle; a first coating comprising one or more deformed components coating the API particle; a second coating comprising silica surrounding and/or partially or fully embedded into the first coating, a matrix former, and a structure former.